Brought to you by 
G1 Therapeutics completes $108.5mm IPO
23 May 2017
Executive Summary
Cancer drug developer G1 Therapeutics Inc. netted $108.5mm through its initial public offering of 7.8mm common shares (including partial exercise of the overallotment) at $15. The company originally intended to sell 6.25mm shares at a range of $15-17 apiece.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
G1 Therapeutics completes $108.5mm IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice